In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Metsera, Inc. is one of them.
Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biotech based in New York, is emerging as an innovative player in obesity and metabolic disease treatments. The company develops next-generation injectable and oral hormone analog peptides designed for potency, scalability, and improved patient adherence.
In 2025, Metsera, Inc.’s lead candidate, MET-233i, an ultra-long-acting amylin analog, showed promising Phase 1 results, with patients achieving up to 8% body weight reduction over five weeks. Its extended half-life supports once-monthly dosing, offering greater convenience and potential compliance benefits compared to existing therapies. MET-233i is being developed both as a standalone treatment and in combination with other obesity medicines in the business’s pipeline.
Another key asset, the GLP-1 receptor agonist MET-097i, is progressing through multiple Phase 2b trials, with data readouts expected later in 2025 and Phase 3 trials planned to begin by year-end. The corporation is preparing to present these results at upcoming medical and investor conferences, signaling growing scientific and market interest.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure. None.
